Kornimate/medical-research-clean huggingface dataset:
virtual therapeutics for mci

Conditions: Mild Cognitive Impairment

Summary: mild cognitive impairment (mci) is a term used to describe the transitional stage that occurs between normal aging and the onset of dementia. spatial disorientation is often considered a significant indicator for diagnosing dementia. numerous studies have documented deficits in both the allocentric and egocentric spatial frames of reference, as well as difficulties in transitioning between them, in individuals with mci. rapid advances in computing technology have enabled researchers to conduct cognitive training and rehabilitation interventions with the assistance of technology. therefore, the aim of the study is to use virtual therapeutics to train mci spatial memory.

the current study aims to design, develop and test virtual therapeutics to train mci spatial memory through virtual reality rehabilitation. 36 participants will be randomly assigned to three different conditions: embodied low-end spatial vr training vs. the treatment as usual (tau; i.e., visuospatial "paper and pencil" stimulation) vs. a non-embodied low-end spatial vr training. the three conditions will consist of at least 8 sessions of 30/40 minutes 3 times a week. the study will measure changes in spatial memory, in particular in egocentric and allocentric memory. each patient will be tested 3 times: 3 weeks before the pre-test (control waiting period), at the pre-test and after the intervention, namely post-test (3 time points).

Eligibility criteria:
inclusion criteria: * a change in cognition recognized by patients or observers (caregiver/examiner) * an objective impairment in one or more cognitive domains using traditional neuropsychological tests; * autonomy or slight dependence on daily life activities; * absence of diagnosis of dementia * absence of cognitive impairment measured by the mini-mental state examination; * aged 65 or over exclusion criteria: * the presence of acute stroke/transient ischemic attack occurred in the 6 months prior to the enrollment visit; * the presence of aphasia and/or neglect; * the presence of other concomitants severe neurological/psychiatric diseases (e.g., hemiparesis, multiple system atrophy, muscular skeletal/orthopedic deficits that limit movement) * the presence of physical and/or functional deficits; * the comorbidity with severe neurological and/or psychiatric diseases (e.g., neoplasms, multiple sclerosis, amyotrophic lateral sclerosis, huntington's disease, schizophrenia, addiction, personality disorder, eating disorder) or with psychiatric conditions not under drug treatment (anxiety-depressive syndrome, bipolarism); * the history of head trauma with loss of consciousness * recurrent vertigo.
acute kidney injury in children after cardiopulmonary bypass

Conditions: Congenital Heart Disease in Children; Cardiopulmonary Bypass

Summary: acute kidney injury (aki) is a common complication in patients with congenital heart defects after cardiopulmonary bypass. the death rate from aki in critically ill children remains high and reaches 60%. the basic criteria for diagnosing and assessing the severity of kidney injury until recently were the level of serum creatinine and the amount of urine released. however, it should be noted that the level of serum creatinine, traditionally used to assess renal function, does not significantly increase until a decrease of more than 50% of the glomerular filtration rate, in addition, its level depends also on some extrarenal causes. artificial blood circulation and hemodilution leads to the preservation of the level of creatinine at sufficiently low levels up to 1-3 days postoperative period. the level of diuresis as well as the level of creatinine is a nonspecific criterion after cardiac surgery and depends on several factors. currently, in the field of acute renal injury studies, progress has been made in the emergence of new biomarkers such as the tissue inhibitor metalloproteinase-2 (timp-2) and insulin-like growth factor binding globulin-7 (igfbp7), which are early markers of acute renal damage. in a study in adult patients, it was shown that the levels of timp-2 and igfbp7 increased in the first 24-48 before the diagnosis of ir-associated renal damage. among pediatric patients with congenital heart defects, such studies are single and only present for the age group 3 and older, which also demonstrated the high specificity and prognostic significance of these biomarkers in the early diagnosis of acute renal damage. it should also be noted that, in spite of the high specificity of the markers described, it is also necessary to note their considerable cost. thus, taking into account the above, it is planned to compare and identify the relationship of these indicators with such parameter as the index of renal vascular resistance, the increase of which in the pre- and postoperative period may serve as a sign of the beginning acute renal injury.


Eligibility criteria:
inclusion criteria: age from 1 month to 1 year presence of congenital heart disease radical correction of the defect in conditions of cardiopulmonary bypass exclusion criteria: inconsistency with age criteria cardiotonic support before surgery acute renal, acute liver failure before surgery

Keywords: acute kidney injury, cardiosurgery
metabolomics of insomnia-related hyperarousal

Conditions: Primary Insomnia

Summary: individuals with insomnia have been shown to have higher overall metabolic rates compared to good sleepers, but it is not known which metabolic processes are involved. the goal of this study is to compare a wide array of metabolic processes in 15 people with insomnia and 15 good sleepers. we hypothesize that there will be distinct metabolic processes that are functioning differently in those with insomnia.


Eligibility criteria:
inclusion criteria: criteria for primary insomnia: * subjective complaint of difficulty initiating or maintaining sleep, waking up too early or nonrestorative sleep * daytime consequences as a result of the poor sleep * duration of at least 1 month * sleep disturbance is not secondary to a medical or psychiatric condition criteria for good sleepers: -subjective report of consistent good sleep exclusion criteria: * significant medical or psychiatric illness * diagnosis of a sleep disorder other than insomnia * women who have been pregnant or lactating in the past 6 months * non-fluency in spoken or written english * current shift work defined as working during the evening or night shift * current use of medications that affect sleep * bmi \>27
fetal ebstein anomaly and tricuspid valve dysplasia registry

Conditions: Ebstein Anomaly; Tricuspid Valve Dysplasia

Summary: ebstein anomaly and tricuspid valve dysplasia (ea/tvd) are rare congenital tricuspid valve malformations that carry among the highest mortality of all congenital heart disease diagnosed in utero. despite the high mortality associated with severe ea/tvd in the fetus, it has only been studied retrospectively. by prospectively enrolling a cohort across multiple centers, many questions may be answered in the perinatal period and beyond. the registry will allow us to understand perinatal and postnatal decision-making in this complex group of patients across centers. given the rarity of the disease, a retrospective arm was added to the original prospective study in may 2024.


Eligibility criteria:
inclusion criteria: 1. mothers of fetuses (ages 14-54) diagnosed with ea/tvd of any severity with normal segmental anatomy (av and va concordance) 1. mothers may be enrolled at any gestational age, up to the day of pregnancy outcome (elective termination of pregnancy, demise, or live-birth) 2. singletons, twins or higher order multiples may be included 2. consent obtained at a participating site exclusion criteria: 1. mothers of fetuses diagnosed with ea/tvd in the context of abnormal segmental anatomy (av and/or va discordance) or other lesions, such as congenitally corrected transposition of the great arteries or pulmonary atresia with intact ventricular septum 2. unable or unwilling to provide consent
comparing nitrous oxide and carbon dioxide for laparoscopic cholecystectomy

Conditions: Pneumoperitoneum

Summary: there is no general agreement about the ideal gas for pneumoperitoneum. co2, now in common use, has not compared to n2o sufficiently to disclose which one has minimal "physiological" invasiveness characters. assigned randomly to carbon dioxide or nitrous oxide group, the hemodynamic and respiratory parameters (heart rate, mean arterial blood pressure, end-tidal co2, minute ventilation, and o2 saturation) before pneumoperitoneum and during it were recorded. pain, as perceived by patients, is measured 2, 4 and 24 hours after the procedure by visual analogue scale. vomiting and use of analgesics and antiemetics were recorded and compared.


Eligibility criteria:
inclusion criteria: * developed gallstones * candidates for laparoscopic cholecystectomy * written informed consent * asa score = 1\&2 exclusion criteria: * signs and complications of gallstones in admission include acute cholecystitis and suppurative cholangitis * complete inability to move * severe physical or mental disorders leading to inability to communicate -pregnancy and * cancer

Keywords: laparoscopic cholecystectomy pneumoperitoneum nitrous oxide carbon dioxide
a multiple dose study of pf-04950615 (rn316) in subjects on high doses of statins

Conditions: Hypercholesterolemia; Dyslipidemia

Summary: this study will investigate the effect of pf-04950615, a new investigational lipid lowering agent, on ldl-c and other lipids.


Eligibility criteria:
inclusion criteria: * on a stable daily dose of atorvastatin, rosuvastatin or simvastatin. * lipids meet the following criteria at screening and prior to dosing: fasting ldl-c greater than 100 mg/dl and fasting tg less than 400 mg/dl exclusion criteria: * history of a cardiovascular or cerebrovascular event or procedure during the past year. * poorly controlled type 1 or type 2 diabetes mellitus. * poorly controlled hypertension.

Keywords: pf-04950615 rn316
a phase iii study to investigate the impact of diamyd in patients newly diagnosed with type 1 diabetes (eu)

Conditions: Type 1 Diabetes Mellitus

Summary: the purpose of this study is to determine whether diamyd (rhgad65 formulated in alum) is effective in preserving the body's own insulin producing capacity in patients recently diagnosed with type 1 diabetes.


Eligibility criteria:
main inclusion criteria: * male and female patients between 10 and 20 years of age * insulin dependent type 1 diabetes mellitus diagnosed within the previous 3 months at time of screening * fasting c-peptide level at time of screening above 0.1 nmol/l * elevated gad65 antibodies (gada) at time of screening main exclusion criteria: * treatment with immunosuppressants or any anti-diabetic medications other than insulin * a history of certain diseases or conditions (e.g. anemia, hiv, hepatitis, epilepsy, head trauma, neurological diseases or cerebrovascular accident, alcohol or drug abuse etc) * treatment with any vaccine within 1 month prior to planned first diamyd dose or planned treatment with vaccine up to 2 months after the last injection with diamyd, excluding the influenza vaccine * participation in other clinical trials with a new chemical entity within the previous 3 months * pregnancy or planned pregnancy within 1 year after the last diamyd dose * presence of associated serious disease or condition which in the opinion of the investigator makes the patient non-eligible for the study

Keywords: diabetes juvenile diabetes diabetes type 1 autoimmune diabetes insulin dependent diabetes type 1 diabetes type 1 diabetes mellitus diamyd rhgad65 gad gad-alum
basis: evaluating sirtuin supplements to benefit elderly trauma patients (bes2t bet)

Conditions: Recovery of Function

Summary: basis: evaluating sirtuin supplements to benefit elderly trauma patients (bes2t bet) a phase i, randomized, double-blind, placebo-controlled, single institutional pilot trial investigating the impact of nicotinamide riboside/pterstilbene (basistm) on functional recovery after traumatic fall in elderly patients .

this phase i pilot study will determine if supplementing with the combination of nr and pter (basistm) is well tolerated and will provide the pretrial data necessary to plan a randomized clinical trial aimed at determining if basistm improves the functional outcome of injured elderly patients. primary objective • to determine if basistm is well tolerated by elderly patients up to 90 days post injury secondary objectives: * to determine if basistm preserves or improves muscular strength, endurance, and activity following traumatic injury in elders. * to determine if basistm preserves or improves physiologic composition (muscle/fat ratio) following traumatic injury in elders. * to determine if basistm decreases 90 day incidence of recurrent falls * to determine the impact of basistm on subjective well-being (pain) and quality of life (eq-5d-5l) * to determine if basistm alters nad and sirtuin activity in inflammatory cells. elderly trauma patients who present after a traumatic injury will be screened and enrolled within 48 hours of their trauma evaluation. baseline status will be determined using functional surveys, physical assessments, and physiologic measurements. patients will be randomized to either basistm or placebo for 90 days. patients will be reassessed at 2 weeks, 6 weeks (optional) and 90 days. activity and heart rate will be monitored continuously using a wrist fitbit device.

Eligibility criteria:
inclusion criteria: 1. ≥ 65 year old 2. patient presenting to trauma bay exclusion criteria: 1. currently taking medication for severe to moderate dementia (see appendix 9) 2. currently taking niacin, nicotinic acid, nicotinamide, or nicotinamide riboside 3. pre-existing immobility (wheel chair or bed bound) 4. renal failure requiring hemodialysis or peritoneal dialysis 5. end-stage liver disease (model for end stage liver disease score ≥ 25) (see appendix 11) 6. intubated prior to enrollment (excluding intubation for surgery) 7. more than 48 hours post-injury 8. thoracic anatomic injury score \> 3 (see appendix 10) 9. other injuries with anatomic injury score \>2, excluding thorax (see appendix 10) 10. hip fractures 11. non-english speaking
monitoring and treatment of extremity trauma for mass casualties in difficult contexts

Conditions: Wounds and Injuries; Traumatic Amputation

Summary: the prospective cohort study, sutra2, assesses the functional and socio-economic status of patients who were operated on for a severe limb injury resulting in amputation or limb preservation 1 and 2 years after the 2010 haiti earthquake.


Eligibility criteria:
inclusion criteria: * patients, with limb injuries due to the earthquake, * who underwent limb surgery, which ended up in limb amputation or limb conservation. exclusion criteria : * limb injury not related to the earthquake * no surgery for the limb injury
copper cu 64-dota-b-fab pet/ct in imaging patients with ovarian and breast cancer

Conditions: Ovarian Carcinoma; Breast Carcinoma

Summary: this pilot clinical trial studies copper cu 64-dota-b-fab positron emission tomography (pet)/computed tomography (ct) in imaging patients with ovarian and breast cancer. cancer antigen (ca)6 is an antigen (substance) found on the surface of several types of cancer cells such as cancer of the ovary and breast. diagnostic procedures, such as copper cu 64-dota-b-fab pet/ct, may help identify ca6 positive tumors and allow doctors to plan better treatment.

primary objectives: i. to determine the dosimetry of 64cu-dota b-fab (copper cu 64-dota-b-fab). secondary objectives: i. to evaluate the safety of 64cu-dota b-fab single administration. ii. to evaluate the ability of 64cu-dota b-fab to detect ca6-positive ovarian and breast cancer lesions. iii. to compare pet results with the immunohistochemistry (ihc) analysis of the excised tumor samples. outline: patients receive copper cu 64-dota-b-fab intravenously (iv) followed by pet/ct 60 minutes post-injection and 24 hours post-injection after completion of study, patients are followed up for 12 months.

Eligibility criteria:
inclusion criteria: ovarian cancer participants 1. patient is ≥ 18 years old at the time of the drug administration 2. participant has suspected or biopsy proven ovarian cancer and is scheduled to undergo surgical excision of the cancerous lesion(s) or participant has biopsy proven ovarian cancer but is not a surgical candidate 3. ability to understand and the willingness to sign a written informed consent document. 4. patient is able to remain still for duration of each imaging procedure breast cancer participants 1. patient is ≥ 18 years old at the time of the drug administration 2. participant has biopsy proven breast cancer and may or may not undergo surgical excision of the cancerous lesion(s) 3. ability to understand and the willingness to sign a written informed consent document. 4. patient is able to remain still for duration of each imaging procedure exclusion criteria: ovarian cancer participants 1. patient is pregnant or breast-feeding 2. patients with contraindications for pet/ct or who cannot complete a pet/ct scan or other study procedures. 3. patients with serious uncontrolled concurrent medical illness that would limit compliance with study requirements 4. patients participating in other research imaging protocols will be excluded from this study. breast cancer participants 1. patient is pregnant or breast-feeding 2. patients with contraindications for pet/ct or who cannot complete a pet/ct scan or other study procedures. 3. patients with serious uncontrolled concurrent medical illness that would limit compliance with study requirements 4. patients participating in other research imaging protocols will be excluded from this study.
treatment of papillary thyroid carcinoma with radiofrequency ablation

Conditions: Papillary Thyroid Cancer; Papillary Thyroid Microcarcinoma

Summary: investigators intend to evaluate the efficiency of radiofrequency ablation (rfa) therapy to treat papillary thyroid carcinoma.

investigators plan to identify patients with small papillary thyroid carcinoma and subject such patients to radiofrequency ablation (rfa) therapy. following rfa procedure patients will be monitored to study the changes in primary tumor volume, development of lymph node involvement, development of distant metastasis and changes in serum thyroid hormone levels. investigators will also assess the stability of these changes (need for repeat therapy) and the safety of the rfa procedure.

Eligibility criteria:
inclusion criteria: * are adults * nodule with papillary thyroid carcinoma meeting the below criteria: * diagnosed by fine needle aspiration (fna) cytology. * size \< 1.5 cm * non-surgical therapy is considered acceptable by the treating physician * radiology evaluation deems the lesion amenable to rfa therapy with minimal risk of complication exclusion criteria: * clinical evidence for a multifocal papillary thyroid malignancy * clinical evidence for local or distant metastatic disease * pregnancy * vocal cord paralysis on contralateral side * coagulopathy or patients on anticoagulation therapy * patients with prior neck surgery or neck radiation * patients with neck anatomy that precludes easy access by rfa * patients with comorbidities deemed too high of a risk for general anesthesia * treatment with another investigational drug or intervention (within 6 weeks of planned rfa). * current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.

Keywords: rfa radiofrequency thyroid cancer ablation techniques ultrasonography
ram cannula vs short nasal prongs for delivering nippv in preterm infants

Conditions: Respiratory Distress Syndrome, Newborn; Noninvasive Ventilation; Infant, Premature; Intubation, Intratracheal

Summary: randomized control trial, ram cannula vs short nasal prongs for delivering non invasive positive pressure ventilation (nippv) for preterm infants

randomized control trial comparing ram cannula to the regular, more investigated short nasal prongs for delivering non invasive positive pressure ventilation (nippv) for preterm infants with respiratory distress.

Eligibility criteria:
inclusion criteria: * gestational age 24-33.6 * physician decision on the need for non invasive ventilation * parental consent exclusion criteria: * pneumothorax before recruitment * significant congenital heart disease or chromosomal disorder
an innovation during the surgical wait; evaluation of the opportunity for intervention

Conditions: Breast Cancer

Summary: the investigators will compare the differences in the scores between the baseline questionnaire (at diagnosis) and the second questionnaire (at treatment) in the rads ii patients that enrolled in pre-treatment trials versus those that don't.


Eligibility criteria:
inclusion criteria: * \>18 years of age * diagnosis of bi-rads 4 and 5 (highly suspicious for carcinoma) on an initial imaging * \>2cm area of disease * provide informed consent exclusion criteria: * previous neo-adjuvant therapy * patients with recurrent disease

Keywords: breast
efficacy of low level laser therapy on i̇njection pain

Conditions: Pediatric Anesthesia; Low Level Laser Theraphy

Summary: the purpose of this study was to compare the pain during needle insertion and injection in supraperiosteal anesthesia with either topical anesthesia (control) or lltt (experimental).


Eligibility criteria:
inclusion criteria: in need of treatment of right and left molar teeth of maxilla, * does not have any systemic disorder, * high level of communication that can provide logical answers to the questions we ask * with parental consent, * volunteers who want to participate in the research * 6-12 years old patients who are compatible with routine dental treatments in the pediatric clinic exclusion criteria: * no need for treatment of right and left molar teeth of maxilla, * has a systemic condition * low level of communication that cannot provide reasonable answers to the questions we ask * without parental consent * do not want to participate voluntarily in the research * do not attend a check-in * patients not in the 6-12 age group

Keywords: pediatric patient injection pain lllt
the effect of the musical toy used during peripheral vascular access on children's pain, fear and parents' satisfaction

Conditions: Pain; Child, Only; Parents

Summary: the research was carried out as a randomized controlled experimental study in order to examine the effects of the child's pain, fear and parent's satisfaction before and after vascular access with a musical toy-xylophone, which is used as a distraction technique for the preparation of the 3-6 year old child hospitalized in the pediatric clinic.

the population of the study consists of children aged 3-6 years who applied to durağan şehit hakan tanrıkulu state hospital pediatric service between january 2022 and december 2022 and needed vascular access. the sample of the study consisted of 70 children (control: 35, experiment: 35) who met the case selection criteria. child and parent descriptive information form, child fear scale (cfs), children's emotional indicator scale (ceis), qucher photographic and numerical rating form (qucher), and nurse-patient collaboration level and parent satisfaction form were used. while the children in the experimental group were playing with a musical toy with their parents, peripheral vascular access was performed.

Eligibility criteria:
inclusion criteria: * the child is between 3-6 years old, * volunteering of parents and children to participate in the research, * the child does not come to the hospital with acute pain, exclusion criteria: * the child has a hearing, vision and mental problem, * the child and the parent do not understand and speak turkish easily, * absence of a primary caregiver,

Keywords: pain fear children parent